EDSA — Edesa Biotech, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1540159 ·
Ontario, Canada
Last close
$1.96
Market Cap
$18.90M
52W High
$20.32
52W Low
$0.72
ADV30
3,019,354
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,412,181 | -5,407,611 | 12,721,195 | 10,332,520 | 3,910,041 |
| Mar 2026 | 0 | — | -4,230,766 | -4,218,332 | 12,384,738 | 10,003,683 | 2,187,921 |
| Dec 2025 | 0 | — | -2,238,958 | -2,247,669 | 14,710,442 | 12,051,748 | 756,163 |
| Sep 2025 | 0 | — | -2,223,098 | -2,228,358 | 13,530,518 | 10,792,172 | 1,078,536 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,907,623
Investing CF
—
Financing CF
$6,979,859
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.62
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-77,896,367
Inventory
—
Receivables
$228,051
ST Investments
—
EBIT TTM
$-14,105,003
Pretax Income TTM
$-14,101,170
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | -7,127,672 | -7,185,523 | 13,530,518 | 1,078,536 | 12,451,982 | -7,322,262 |
| Sep 2024 | 0 | -6,316,467 | -6,170,045 | 3,813,982 | 1,832,827 | 1,981,155 | -4,890,205 |
| Sep 2023 | 0 | -8,641,719 | -8,374,415 | 8,890,437 | 1,841,637 | 7,048,800 | -6,636,483 |
| Sep 2022 | 0 | -17,590,533 | -17,548,924 | 11,575,728 | 2,184,439 | 9,391,289 | -12,279,302 |
TTM Snapshot
Revenues TTM
$1,152,762
NetIncome TTM
$-14,101,970
OpCashFlow TTM
—
Assets (Latest)
$12,721,195
Forward EPS
$-1.93
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATOS | ATOSSA THERAPEUTICS, INC. | $18.96M | $1.90 | — |
| CELU | Celularity Inc | $18.53M | $0.57 | — |
| IGC | IGC Pharma, Inc. | $19.43M | $0.19 | — |
| COCP | Cocrystal Pharma, Inc. | $19.46M | $1.01 | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $17.90M | $0.04 | — |
News headlines (Yahoo Finance, 1h cache)
Edesa Biotech Granted Orphan Designation for Paridiprubart for the Treatment of ARDS by the European Commission
2026-11-17 14:25 · Yahoo
Edesa Biotech Signs Japan Licensing Agreement With Kyorin for Paridiprubart Worth Up to $146 Million
2026-11-09 11:54 · Yahoo
Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan
2026-11-09 11:00 · Yahoo
Edesa Biotech to Present at Guggenheim Healthcare Innovation Conference
2026-11-04 21:30 · Yahoo
Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study
2026-10-15 13:15 · Yahoo
EDSA: Recruitment in Phase 2 Vitiligo Study Set to Get Underway
2026-08-24 08:02 · Yahoo
Edesa Biotech Stock Sinks After Fresh Capital Raise
2026-08-20 10:20 · Yahoo
Edesa Biotech Announces Proposed Public Offering
2026-08-19 20:01 · Yahoo
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
2026-08-13 20:15 · Yahoo
EDSA: Positive Exploratory Data in Patients with AKI
2026-07-02 12:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.